19F NMR Allows the Investigation of the Fate of Platinum(IV) Prodrugs in Physiological Conditions
- 20 November 2021
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 61 (4) , e202114250
Abstract
PtIV prodrugs can overcome resistance and side effects of conventional PtII anticancer therapies. By 19F‐labeling of a PtIV prodrug (Pt‐FBA, FBA=p‐fluorobenzoate), the activation under physiological conditions could be investigated. Unlike single‐electron reductants, multi‐electron agents can efficiently promote the two electrons reduction of PtIV to PtII. The activation of Pt‐FBA in cell lysate is highly dependent upon the type of cancer cells. When administered to E. coli, Pt‐FBA is reduced intracellularly and free FBA can shuttle out of the cell. The reduction rate greatly increases by inducing metallothionein overexpression and is lowered by addition of ZnII ions. When injected into mice, Pt‐FBA undergoes fast reduction in the bloodstream accompanied by metabolic degradation of FBA; nevertheless, unreduced Pt‐FBA can accumulate to detectable levels in liver and kidneys. The 19F NMR approach has the advantage of avoiding the interference of all background signals.Keywords
Funding Information
- National Natural Science Foundation of China (22177109, 21877103, 52021002)
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017WBZFHL)
This publication has 43 references indexed in Scilit:
- Quantitative measurement of the reduction of platinum(iv) complexes using X-ray absorption near-edge spectroscopy (XANES)Metallomics, 2012
- Photolysis and Thermolysis of Platinum(IV) 2,2′‐Bipyridine Complexes Lead to Identical Platinum(II)–DNA AdductsChemistry – A European Journal, 2010
- 19F NMR Studies of α-Synuclein Conformation and FibrillationBiochemistry, 2009
- Is Glutathione the Major Cellular Target of Cisplatin? A Study of the Interactions of Cisplatin with Cancer Cell ExtractsJournal of Medicinal Chemistry, 2009
- Investigations using fluorescent ligands to monitor platinum(iv) reduction and platinum(ii) reactions in cancer cellsDalton Transactions, 2009
- Current Status and Future Prospects for Satraplatin, an Oral Platinum AnalogueClinical Cancer Research, 2008
- Elemental Tomography of Cancer-Cell Spheroids Reveals Incomplete Uptake of Both Platinum(II) and Platinum(IV) ComplexesJournal of the American Chemical Society, 2007
- Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitroCancer Chemotherapy and Pharmacology, 2005
- Experimental and Theoretical Studies on the Pharmacodynamics of Cisplatin in Jurkat CellsChemical Research in Toxicology, 2004
- The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cellsJBIC Journal of Biological Inorganic Chemistry, 2003